This trial is evaluating whether Treatment will improve 1 primary outcome, 1 secondary outcome, and 1 other outcome in patients with Septal Defect, Heart. Measurement will happen over the course of 12 months.
This trial requires 640 total participants across 1 different treatment group
This trial involves a single treatment. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
Patients from any state can participate in this trial, so long as they are able to attend all treatment sessions.
In order to understand how insurance coverage works for this trial, you will need to contact the study coordinator.